

# Free-living arm swing range of motion as a digital progression marker of Parkinson's disease




E. Post<sup>1,2</sup>, T. M. van Laarhoven<sup>2</sup>, N. A. Timmermans<sup>1</sup>, Y. P. Raykov<sup>3</sup>, M. A. Little<sup>4</sup>, J. Nonnekes<sup>1</sup>, T. M. Heskes<sup>2</sup>, B. R. Bloem<sup>1</sup>, L. J. W. Evers<sup>1,2</sup>

<sup>1</sup> Center for Expertise for Parkinson and Movement Disorders, department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands; <sup>2</sup> Institute for Computing and Information Sciences, Radboud University, Nijmegen, the Netherlands; <sup>3</sup> University of Nottingham, United Kingdom; <sup>4</sup> University of Birmingham, United Kingdom

## Introduction

- **Reduced arm swing** during gait is an early and progressive motor sign of Parkinson's Disease (PD), making it a promising marker for disease progression and treatment response.
- **Wrist sensors** can be used to reliably measure the arm swing range of motion in daily life<sup>1</sup>.
- This study evaluates the **sensitivity to disease progression** of such measures in a large, longitudinal free-living PD cohort.

## Study design



- 320 early-stage ambulatory PD participants wore a **wrist sensor** on their preferred side continuously (median 21 hours/day) for at least **2 years in free-living conditions** in the Personalized Parkinson Project<sup>3</sup>.
- Participants either used dopaminergic medication (*medicated*) or not (*unmedicated*) during the study; those who initiated treatment were excluded.

Table 1: Number of participants per stratification

|                            | Medicated | Unmedicated |
|----------------------------|-----------|-------------|
| <b>Most affected side</b>  | 184       | 18          |
| <b>Least affected side</b> | 113       | 5           |

- The weekly (1) median and (2) 95<sup>th</sup> percentile range of motion (RoM) were derived from accelerometer and gyroscope data using the Parkinson's disease Digital Markers (*ParaDigMa*) toolbox<sup>2</sup>.


## Methodology

- Bootstrapped two year **standardized response mean (SRM)** with 95% CI to assess sensitivity to progression.
- Comparison with the sum of MDS-UPDRS Part III unilateral non-tremor items (subscore).
- **Ordinary least squares (OLS) regression** to examine the impact of clinical covariates on observed changes.


## Results

— Most affected side — Least affected side

### 1. Digital measures over time (median, IQR)




### 2. Sensitivity to two-year progression



\* Results of unmedicated participants wearing the watch on the least affected side (N = 5) are shown with dashed lines due to unreliable (bootstrapping) results when having a small number of participants.

### 3. Effect of clinical covariates on change



## Conclusions

- Digital measures capture progression of arm swing impairment, but this signal is masked by dopaminergic treatment.
- In unmedicated patients, digital arm swing metrics demonstrate sensitivity to progression comparable to the MDS-UPDRS Part III unilateral non-tremor score of the most affected side.

### References

1. Post et al. Quantifying arm swing in Parkinson's disease: a method accounting for arm activities during free-living gait. *J NeuroEngineering Rehabil* 22, 37 (2025).
2. Post et al. ParaDigMa: A toolbox for deriving Parkinson's disease Digital Markers from real-life wrist sensor data (v1.0.0). Zenodo.
3. Bloem et al. The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease. *BMC Neurol*. 2019 Jul 17;19(1):160.

### Acknowledgements

This work was financially supported by the Michael J Fox Foundation (grant #020425), the Dutch Research Council (grant #ASDI.2020.060 & grant #2023.010), the Dutch Research Council Long-Term Program (project #KICH3.LTP.20.006, financed by the Dutch Research Council, Verily, and the Dutch Ministry of Economic Affairs and Climate Policy), and the Dutch Ministry of Economic Affairs (Topconsortium voor Kennis en Innovatie, Life Sciences & Health, grant #LSHM20090-H048).